文献速递肝病

包含肌少症的模型在预测肝硬化肝移植候选者等待名单死亡率方面优于MELD评分:一项全国队列的竞争风险分析

A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort.
PubMed 文献 · J Hepatol · 2017-12-06

该研究基于2007—2014年Eurotransplant登记中连续列入肝移植的585例肝硬化患者,用CT测骨骼肌量并做竞争风险分析,发现肌少症与等待名单死亡相关,尤其在MELD≤15者中更明显;MELD-肌少症评分(MELD+10.35×肌少症)三个月死亡判别力(c指数0.820)低于单纯MELD(c指数0.839),含肌少症、MELD、列名单前肝性脑病及受者年龄的模型c指数为0.851。

要点

  • 585例候选中肌少症254例(43.4%),肌少症者等待名单生存较无肌少症者短(p<0.001)。
  • 该效应在MELD≤15患者中更明显。
  • MELD-肌少症评分c指数0.820,低于单纯MELD的0.839。

核心结论

  • 肌少症与肝硬化肝移植候选者等待名单死亡相关,尤其在MELD评分较低者中。
  • MELD-肌少症评分在该队列中得到成功验证,但在预测等待名单死亡方面加入肌少症的附加价值有限。

研究设计与样本

  • 研究识别2007—2014年Eurotransplant登记中连续列入肝移植的肝硬化患者,并用计算机断层扫描测量骨骼肌量。
  • 采用竞争风险分析比较有无肌少症患者的生存,计算一致性(c)指数评估MELD与MELD-肌少症评分性能,并构建最佳预测模型的列线图。

主要发现

  • 共纳入585例患者,中位MELD评分14(四分位距9—19),其中254例(43.4%)被判定为有肌少症。
  • 有肌少症者中位等待名单生存较无肌少症者短(p<0.001),该效应在MELD≤15患者中更明显。
  • MELD-肌少症评分对三个月死亡的判别力(c指数0.820)低于单纯MELD评分(c指数0.839)。
  • 除肌少症与MELD评分外,其他预测变量包括列名单前发生肝性脑病及受者年龄;包含所有这些变量的模型c指数为0.851。

关键数值与推荐

  • MELD-肌少症评分计算公式为MELD+10.35×肌少症。
  • MELD-肌少症评分c指数0.820,单纯MELD评分c指数0.839(用于三个月死亡判别)。
  • 包含肌少症、MELD评分、列名单前肝性脑病及受者年龄的模型c指数0.851。

临床怎么用

  • 作者指出,将肌少症测量加入当前供者与器官分配系统未显示附加价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Frail patients with low model for end-stage liver disease (MELD) scores may be under-prioritised. Low skeletal muscle mass, namely sarcopenia, has been identified as a risk factor for waiting list mortality. A recent study proposed incorporating sarcopenia in the MELD score (MELD-Sarcopenia score). We aimed to investigate the association between sarcopenia and waiting list mortality, and to validate the MELD-Sarcopenia score (i.e. MELD + 10.35 * Sarcopenia). METHODS: We identified consecutive patients with cirrhosis listed for liver transplantation in the Eurotransplant registry between 2007-2014 and measured skeletal muscle mass on computed tomography. A competing risk analysis was used to compare survival of patients with and without sarcopenia, and concordance (c) indices were calculated to assess performance of the MELD and MELD-Sarcopenia score. We created a nomogram of the best predictive model. RESULTS: We included 585 patients with a median MELD score of 14 (interquartile range 9-19), of which 254 (43.4%) were identified as having sarcopenia. Median waiting list survival was shorter in patients with sarcopenia than those without (p <0.001). This effect was even more pronounced in patients with MELD ≤15. The discriminative performance of the MELD-Sarcopenia score (c-index 0.820) for three-month mortality was lower than MELD score alone (c-index 0.839). Apart from sarcopenia and MELD score, other predictive variables were occurrence of hepatic encephalopathy before listing and recipient age. A model including all these variables yielded a c-index of 0.851. CONCLUSIONS: Sarcopenia was associated with waiting list mortality in liver transplant candidates with cirrhosis, particularly in patients with lower MELD scores. The MELD-Sarcopenia score was successfully validated in this cohort. However, incorporating sarcopenia in the MELD score had limited added value in predicting waiting list mortality. LAY SUMMARY: In this study among patients with liver cirrhosis listed for liver transplantation, low skeletal muscle mass was associated with mortality on the waiting list, particularly in patients who were listed with low priority based on a low MELD score. However, adding these measurements to the currently used system for donor and organ allocation showed no added value.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. van Vugt JLA, Alferink LJM, Buettner S, et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort. J Hepatol. 2017. PMID: 29221886. doi:10.1016/j.jhep.2017.11.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。